1-20 of 46
Jian Huang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3974: Macronutrient composition dictates MASH-associated HCC immunosurveillance through microbiota alteration and metabolic adaptation

Nicolas T. Ryujin, Jian Huang, Albert Nguyen, Jared Edwards, Yuhe Cheng, Jessica Wen, Ashish Damania, Nadim Ajami, Spencer Rosario, Mark Long, Ludmil Alexandrov, Shabnam Shalapour
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3974.
https://doi.org/10.1158/1538-7445.AM2024-3974
Published: 22 March 2024
View articletitled, Abstract 3974: Macronutrient composition dictates MASH-associated HCC immunosurveillance through microbiota alteration and metabolic adaptation
Journal Articles

FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation

Yi Ouyang, Ziwei Ou, Wenlong Zhong, Jin Yang, Sha Fu, Nengtai Ouyang, Junyu Chen, Longhao Xu, Daqin Wu, Junan Qian, Yi Lin, Tianxin Lin, Jian Huang
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4030–4046.
https://doi.org/10.1158/0008-5472.CAN-23-1065
Published: 15 December 2023
View articletitled, FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation
Open the PDF for FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation in another window
Includes: Supplementary data
Journal Articles

NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer

Ruihui Xie, Liang Cheng, Ming Huang, Lin Huang, Ziyue Chen, Qiang Zhang, Hong Li, Junlin Lu, Hongjin Wang, Qianghua Zhou, Jian Huang, Xu Chen, Tianxin Lin
Journal: Cancer Research
Cancer Res (2023) 83 (10): 1666–1683.
https://doi.org/10.1158/0008-5472.CAN-22-2233
Published: 15 May 2023
View articletitled, NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer
Open the PDF for NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 1694: Loss ofZNF251stimulates NHEJ resulting in PARP inhibitor resistance inBRCA1-mutated cancer cells

Jian Huang, Tomasz Skorski
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1694.
https://doi.org/10.1158/1538-7445.AM2023-1694
Published: 04 April 2023
View articletitled, Abstract 1694: Loss ofZNF251stimulates NHEJ resulting in PARP inhibitor resistance inBRCA1-mutated cancer cells
Journal Articles

Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation

Kurt A. Schalper, Atsushi Matsuda, Michelle Ganno-Sherwood, Angel E. Maldonado-Lopez, Emily Rosentrater, Angelo Porciuncula, Dong Mei Zhang, Camilla L. Christensen, Samantha A. Merrigan, Tiquella Hatten, Hong Myung Lee, Min Young Lee, Linlin Dong, Jian Huang, Natasha Iartchouk, Jianing Wang, He Xu, Tomoki Yoneyama, Konstantin I. Piatkov, Carole E. Harbison, Alex Parent, Neil Lineberry, Adnan O. Abu-Yousif, Vicky Appleman
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1841.
https://doi.org/10.1158/1538-7445.AM2023-1841
Published: 04 April 2023
View articletitled, Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation
Journal Articles

Abstract 6658: Prevalence of PD-L1 expression and its correlation with tumor biomarkers in the Chinese muscle invasive urothelial bladder carcinoma patients

Yu Fan, Tao Dai, Dahong Zhang, Hongqian Guo, Fangjian Zhou, Benkang Shi, Shaogang Wang, Zhigang Ji, Chunxi Wang, Xudong Yao, Qiang Wei, Nanhui Chen, Jinchun Xing, Jinjian Yang, Chuize Kong, Jian Huang, Dingwei Ye, Liqun Zhou
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6658.
https://doi.org/10.1158/1538-7445.AM2023-6658
Published: 04 April 2023
View articletitled, Abstract 6658: Prevalence of PD-L1 expression and its correlation with tumor biomarkers in the Chinese muscle invasive urothelial bladder carcinoma patients
Journal Articles

Abstract 823: ABL1 kinase regulates leukemia phenotype and response to therapy

Konstantin Golovine, Zhaorui Lian, Kumaraswamy Naidu Chitrala, Gleb Ablakov, Margaret Nieborowska-Skorska, Jian Huang, Tomasz Skorski
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 823.
https://doi.org/10.1158/1538-7445.AM2022-823
Published: 15 June 2022
View articletitled, Abstract 823: ABL1 kinase regulates leukemia phenotype and response to therapy
Journal Articles

Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer

Mingjie An, Hanhao Zheng, Jian Huang, Yan Lin, Yuming Luo, Yao Kong, Mingrui Pang, Dingwen Zhang, Jiabin Yang, Jiancheng Chen, Yuanlong Li, Changhao Chen, Tianxin Lin
Journal: Cancer Research
Cancer Res (2022) 82 (12): 2239–2253.
https://doi.org/10.1158/0008-5472.CAN-21-4349
Published: 15 June 2022
View articletitled, Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer
Open the PDF for Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer

Xiaojia Wang, Jian Huang
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-27-02.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-27-02
Published: 15 February 2022
View articletitled, Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer
Journal Articles

Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, Changping Shan, Xian Wang, Xi Yan, Jian Zhang, Yue Zhang, Jiani Wang, Liang Zhang, Ying Lin, Jifeng Feng, Qianjun Chen, Jian Huang, Yongkui Lu, Hongsheng Li, Jinsheng Wu, Jing Cheng, Yanrong Hao, Cuizhi Geng, Min Lu, Yanping Li, Xi Chen, Lihua Song, Xueying Wu, Changlu Hu, Xinhong Wu, Xiaojia Wang, Yueyin Pan, Yuehong Cui, Guohua Yu, Sanyuan Sun
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS1-06.
https://doi.org/10.1158/1538-7445.SABCS21-GS1-06
Published: 15 February 2022
View articletitled, Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Journal Articles

Abstract P5-18-06: Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study

Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Fei Wu, Shulin Liu, Xiang Lin, Jianjun Zou
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-18-06.
https://doi.org/10.1158/1538-7445.SABCS21-P5-18-06
Published: 15 February 2022
View articletitled, Abstract P5-18-06: Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
Journal Articles

Abstract P5-18-10: Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study

Min He, Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Shulin Liu, Ping Yan, Jianjun Zou
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-18-10.
https://doi.org/10.1158/1538-7445.SABCS21-P5-18-10
Published: 15 February 2022
View articletitled, Abstract P5-18-10: Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
Journal Articles

Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study

Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Tao Zhang, Jianjun Zou
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-08.
https://doi.org/10.1158/1538-7445.SABCS21-PD8-08
Published: 15 February 2022
View articletitled, Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study
Journal Articles

Abstract P1-17-04: Hormone therapy (HT) brings more survival benefits than capecitabine (CAP) as maintenance therapy following the 1st-line chemotherapy in HR+/HER2-ABC/MBC: Update primary endpoint of OVERSTEP(ZJCHBC001)

Xiao-Jia Wang, Jian Huang, Xi-ying Shao, Li Cai, Yong-mei Yin, Li-li Zhang, Peng Shen, Yan-xia Shi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-17-04.
https://doi.org/10.1158/1538-7445.SABCS21-P1-17-04
Published: 15 February 2022
View articletitled, Abstract P1-17-04: Hormone therapy (HT) brings more survival benefits than capecitabine (CAP) as maintenance therapy following the 1st-line chemotherapy in HR+/HER2-ABC/MBC: Update primary endpoint of OVERSTEP(ZJCHBC001)
Journal Articles

Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study

Jian Zhang, Dongmei Ji, Li Cai, Herui Yao, Min Yan, Xiaojia Wang, Weina Shen, Yiqun Du, Hui Pang, Xiuping Lai, Huiai Zeng, Jian Huang, Yan Sun, Xinxin Peng, Junfang Xu, Jing Yang, Fei Yang, Ting Xu, Xichun Hu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-10.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-10
Published: 15 February 2022
View articletitled, Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study
Journal Articles

Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial

Xiaojia Wang, Jian Huang, Yabing Zheng, Xiying Shao, Wenming Cao, Zhanhong Chen, Yanxia Shi, Li Cai, Wenyan Chen, Zhen Guo, Jian Liu, Peng Shen, Yiding Chen, Xian Wang, Huiping Li, Man Li
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-31.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-31
Published: 15 February 2022
View articletitled, Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial
Journal Articles

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Silvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, Konstantin Golovine, Katherine Sullivan-Reed, Wangisa M.B. Dunuwille, Joseph Nacson, Michael Hulse, Kelsey Keith, Jozef Madzo, Lisa Beatrice Caruso, Zachary Gazze, Zhaorui Lian, Antonella Padella, Kumaraswamy N. Chitrala, Boris A. Bartholdy, Ksenia Matlawska-Wasowska, Daniela Di Marcantonio, Giorgia Simonetti, Georg Greiner, Stephen M. Sykes, Peter Valent, Elisabeth M. Paietta, Martin S. Tallman, Hugo F. Fernandez, Mark R. Litzow, Mark D. Minden, Jian Huang, Giovanni Martinelli, George S. Vassiliou, Italo Tempera, Katarzyna Piwocka, Neil Johnson, Grant A. Challen, Tomasz Skorski
Journal: Cancer Research
Cancer Res (2021) 81 (19): 5089–5101.
https://doi.org/10.1158/0008-5472.CAN-20-3761
Published: 01 October 2021
View articletitled, TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
Open the PDF for TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract PS13-25: Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study

Zefei Jiang, Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Christina Pimentel Oppermann, Yunpeng Liu, Romulo Costa, Man Li, Xi Chen, Ying Cheng, Quchang Ouyang, Ning Liao, Xiaojia Wang, Xinhong Wu, Jifeng Feng, Roberto Hegg, Govindbabu Kanaka Setty, Amit Agarwal, Jyoti Bajpai, Jing Cheng, Gustavo Girotto, Chanchal Goswami, Wenjing Hu, Jian Huang, MA Coccia Portugal, Jin Yang, Rongsheng Zheng, Fabio Andre Franke, Qiang Liu, Yunjiang Liu, Yongkui Lu, Cristiano Souza, Shiying Yu, Nalini Kilara, Harsha Panchal, Ashish Singh, Shona Nag, Jian Liu, Bernardo Rapoport, Neonyana Keorapetse Rebecca Tabane, Hongxia Wang, Ning Wang, Rubing Han, Wanli Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS13-25.
https://doi.org/10.1158/1538-7445.SABCS20-PS13-25
Published: 15 February 2021
View articletitled, Abstract PS13-25: Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
Journal Articles

Abstract PS13-01: Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer

Jian Huang, Xiying Shao, Li Cai, Yanxia Shi, Zhanhong Chen, Ping Huang, Yongmei Yin, Lili Zhang, Peng Shen, Wenming Cao, Weiwu Ye, Yuan Huang, Caijin Lou, Lei Lei, Yabin Zheng, Weibin Zou, Junqing Chen, Xiaojia Wang
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS13-01.
https://doi.org/10.1158/1538-7445.SABCS20-PS13-01
Published: 15 February 2021
View articletitled, Abstract PS13-01: Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer
Journal Articles

Abstract 3174: Genomic alterations of TGFβ signaling genes as novel biomarkers for immunotherapy in patients with non-small cell lung cancer

Shuben Li, Chengzhi Zhou, Jian Huang, Shiyue Zhang, Jiqiang He, Hui Chen, Shaohua Yuan, Weiwei Shi
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3174.
https://doi.org/10.1158/1538-7445.AM2020-3174
Published: 15 August 2020
View articletitled, Abstract 3174: Genomic alterations of TGFβ signaling genes as novel biomarkers for immunotherapy in patients with non-small cell lung cancer